A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancer

ABSTRACT: Interventions: Panitumumab with irinotecan/S-1(IRIS) S-1,80-120mg/body for twice daily 14 consecutive days followed by 2 weeks rest combined with intravenous CPT-11 100mg/m^2 and P-mab 6mg/kg(weight) given on day1,15 every 4 weeks until disease progression or unmanageable toxicity. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Kras Wild Type Metastatic Colorectal Cancer

PROVIDER: 2623902 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR